- Home
- OMER vs AGNT Comparison
OMER vs AGNT Comparison
Compare OMER & AGNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OMER | AGNT |
|---|---|---|
| Founded | 1994 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 844.6M | 708.6M |
| IPO Year | 2008 | 2010 |
Fundamental Metrics
Financial Performance| Metric | OMER | AGNT |
|---|---|---|
| Price | $19.06 | $4.08 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $32.50 | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 1.2M |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 98.15 | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | $29,868,000.00 | ★ $500,147,681.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $233.22 | N/A |
| P/E Ratio | $24.61 | ★ N/A |
| Revenue Growth | N/A | ★ 220.39 |
| 52 Week Low | $3.94 | $3.66 |
| 52 Week High | $19.65 | $5.79 |
Technical Indicators
Market Signals| Indicator | OMER | AGNT |
|---|---|---|
| Relative Strength Index (RSI) | 71.42 | 46.27 |
| Support Level | $18.00 | $3.76 |
| Resistance Level | $19.65 | $4.44 |
| Average True Range (ATR) | 0.88 | 0.20 |
| MACD | -0.14 | -0.04 |
| Stochastic Oscillator | 74.55 | 28.18 |
Price Performance
Historical ComparisonAbout OMER Omeros Corporation
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
About AGNT AGNT Inc. Common Stock
AGNT Inc is a multi-model real estate platform, with brands including eXp Realty, eXp Commercial, NextHome, FrameVR.io, and SUCCESS Enterprises. The group prioritizes transparency, innovation, and long-term value for agents, franchise owners, staff, and shareholders.